Modality
Cell Therapy
MOA
GLP-1/GIP
Target
CD19
Pathway
Amyloid
Breast CaParkinson'sHS
Development Pipeline
Preclinical
~Oct 2023
→ ~Jan 2025
Phase 1
Apr 2025
→ Jan 2028
Phase 1Current
NCT03844299
2,215 pts·Breast Ca
2025-04→2028-01·Not yet recruiting
2,215 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-031.8y awayPh2 Data· Breast Ca
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P1/2
Not yet…
Catalysts
Ph2 Data
2028-01-03 · 1.8y away
Breast Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03844299 | Phase 1/2 | Breast Ca | Not yet recr... | 2215 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| VYG-2926 | Voyager | NDA/BLA | CD19 |